Moore, John P. R.
Shehabi, Yahya
Reade, Michael C.
Bailey, Michael
Fraser, John F.
Murray, Lauren
Anstey, Christopher
Singer, Mervyn
Funding for this research was provided by:
Wishlist (2016-08)
Sunshine Coast Hospital and Health Service SERTF (2016-017)
Article History
Received: 16 March 2022
Accepted: 12 November 2022
First Online: 22 November 2022
Declarations
:
: This study was registered (ANZCTR.org.au ACTRN12616001200471). The study was approved by The Prince Charles Hospital Ethics Committee, Rode Rd, Chermside, Brisbane 4032, Australia (reference number HREC/16/QPCH/141) and was conducted in accordance with the Declaration of Helsinki. Written informed consent for participation was obtained from all patients.
: Written informed consent for publication was obtained from all patients.
: Dr. Shehabi reports the parent SPICE III trial was funded by the NHMRC and an in-kind support of study drug dexmedetomidine from Pfizer and Orion Pharma. No other potential conflict of interest relevant to this article is reported.